Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: mosquito-borne diseases vaccine - SEEK

Drug Profile

Research programme: mosquito-borne diseases vaccine - SEEK

Latest Information Update: 28 May 2020

At a glance

  • Originator PepTcell
  • Developer Imutex; SEEK
  • Class Parasitic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Parasitic infections; Viral infections; Zika virus infection

Most Recent Events

  • 28 May 2020 No recent reports of development identified for preclinical development in Zika-virus-infection in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for research development in Parasitic-infections(Prevention) in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for research development in Viral-infections(Prevention) in United Kingdom

Development Overview

Introduction

Imutex, a joint venture company of SEEK (formerly PepTcell) and hVIVO, is developing a protein-based vaccine against mosquito-borne diseases, including Zika virus, malaria, dengue and West Nile virus. The company's approach is based on the assumption that exposure to molecules in mosquito saliva could provide immunological protection against infections transmitted by mosquitoes. The company is determining if there are mosquito proteins that are involved in the infection process, and whether a targeted immune response could be induced against such proteins. It is hypothesised that immunisation with the vaccine would provide simultaneous protection against several different mosquito-borne diseases. In addition to providing disease protection in the vaccinated individual, ingestion of blood from the vaccinated individual by a mosquito could interact with antibody targets inside the insect, potentially reducing survival of the mosquito population. Preclinical development is underway in the UK.

In December 2010, PepTcell changed its name to SEEK [1] .

As at July 2016, no recent reports of development had been identified for research development in Parasitic-infections (Prevention) in United Kingdom, research development in Viral-infections (Prevention) in United Kingdom.

As at May 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in United Kingdom.

Company Agreements

In April 2016, SEEK granted Imutex a worldwide license of the flu and mosquito-borne disease vaccine platforms, and will provide services in exchange for £7 million in cash consideration and a downstream commercialisation royalty [2] .

Key Development Milestones

Imutex, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), plans to conduct a "First in Man" phase I study of Zika virus vaccine in the US [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Parasitic vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

    J07X (Other vaccines)

  • EPhMRA code

    J7 (Vaccines)

    J7C (All Other Vaccines)

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Parasitic infections - Prevention No development reported (Research) United Kingdom unspecified / unspecified SEEK 16 Jul 2016
Viral infections - Prevention No development reported (Research) United Kingdom unspecified / unspecified SEEK 16 Jul 2016
Zika virus infection - - No development reported (Preclinical) United Kingdom unspecified / unspecified Imutex 28 May 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
PepTcell Originator England
SEEK Owner England
Imutex Licensee United-Kingdom
National Institute of Allergy and Infectious Diseases Collaborator USA
hVIVO Collaborator United-Kingdom

Development History

Event Date Update Type Comment
28 May 2020 Phase Change - No development reported No recent reports of development identified for preclinical development in Zika-virus-infection in United Kingdom Updated 28 May 2020
16 Jul 2016 Phase Change - No development reported No recent reports of development identified for research development in Parasitic-infections(Prevention) in United Kingdom Updated 16 Jul 2016
16 Jul 2016 Phase Change - No development reported No recent reports of development identified for research development in Viral-infections(Prevention) in United Kingdom Updated 16 Jul 2016
22 Apr 2016 Licensing Status Flu and mosquito-borne disease vaccine platforms licensed to Imutex worldwide [2] Updated 28 Apr 2016
22 Apr 2016 Phase Change - Preclinical Preclinical trials in Zika virus infection in United Kingdom (unspecified route) Updated 28 Apr 2016
22 Apr 2016 Trial Update Imutex plans a phase I trial for Zika virus infection in USA [2] Updated 28 Apr 2016
01 Dec 2010 Company Involvement PepTcell is now called SEEK Updated 24 Dec 2010
21 Oct 2009 Phase Change Early research in Parasitic infections in United Kingdom (unspecified route) Updated 21 Oct 2009
21 Oct 2009 Phase Change Early research in Viral infections in United Kingdom (unspecified route) Updated 21 Oct 2009

References

  1. PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

    Media Release
  2. hVIVO Announces a Joint Venture Investment with the SEEK Group to Develop Vaccines against Flu and Zika Infections.

    Media Release
Back to top